🧬 Organ-specific bioregulation

5 mechanistic pathways · 33 options

A genuinely different theory of use, and it deserves to be understood on its own terms rather than shoehorned into a goal. Vladimir Khavinson's group at the St Petersburg Institute of Bioregulation isolated short peptides from animal organs and proposed that each acts on the tissue it came from — binding DNA in the promoter regions of that tissue's own genes and restoring age-declined expression. So you don't take a bioregulator for a symptom; you take it for an organ. Be clear-eyed about the evidence. This is a large, internally consistent, decades-long Russian research programme with reported results — including long-term mortality data — that Western groups have essentially never attempted to replicate. That is not the same as having been refuted, and it is not the same as being established. The gene-promoter binding mechanism is published and plausible; the clinical claims rest almost entirely on one institution. Both halves of that sentence matter. Dosing convention across the class: short cycles (10–20 days), repeated a few times a year, rather than continuous use.

Nothing here is ranked by evidence tier. A lot of what works in this space has never had the trial run, and sorting by trial count would bury exactly the compounds you came looking for. The tier is a label. The mechanism is the map.

The pathways

Thymus & immune

5 options

The original and best-supported target — the thymus involutes with age on a schedule you can almost set a watch by, which makes it the most defensible place to argue that restoring a tissue signal could matter.

Brain & pineal

5 options

The pineal peptides carry the programme's boldest claims — circadian restoration and telomerase activation. They are also the ones people have the most subjective experience with, which cuts both ways.

Endocrine & reproductive

7 options

Organ-specific peptides for the glands. Note how this maps onto the hormonal goals — the bioregulator argument is upstream of hormone replacement rather than an alternative to it.

Vascular, cardiac & structural

7 options

The tissues where age-related decline is most measurable — and where, if a tissue-specific signal did what the theory claims, you would expect to be able to detect it.

Liver, kidney, gut & lung

9 options

The clearance and barrier organs. Each has its own peptide in the series, which is the clearest illustration of how the whole model works — one tissue, one signal.

Test before you choose a pathway

Every route below can be argued for on mechanism. Only bloodwork tells you which one is actually your problem — and picking the wrong pathway is the most common reason someone concludes "none of this works". Across all 5 pathways, these are the 19 markers worth having in front of you first.

The next step

You have the pathways. Here is the stack.

The Bioregulator Blueprint names the one compound I would start with in each of these 5 pathways, what it was chosen over, and why — plus 23 options to swap in or stack on top, every one of them priced and linked.

Free, no email. The week-by-week schedule is the part that lives in the Academy.

Open The Bioregulator Blueprint →

The protocols behind these

Dosing, stacking and cycle timing live inside the Academy, alongside the full interactive Vault and the Bloodwork Protocols.

Join the Academy — $10/mo →

← Open Organ-specific bioregulation in the interactive Vault · All 21 goals

Frequently asked questions

How many ways are there to approach organ-specific bioregulation?

This goal is broken into 5 distinct mechanistic pathways — Thymus & immune; Brain & pineal; Endocrine & reproductive; Vascular, cardiac & structural and others — across 33 compounds and supplements. Each pathway is a different argument about how the body gets there, so the useful question is which one matches where you are actually stuck.

Which pathway should I start with for organ-specific bioregulation?

The one that matches your actual limitation, which bloodwork usually settles faster than guessing. An appetite drug does nothing for someone who already undereats, and a thyroid intervention does nothing if your thyroid is fine. Each pathway page lists the markers that tell you whether it is your problem.

Are the 5 organ-specific bioregulation pathways ranked best to worst?

No. The 5 pathways are listed in mechanistic order, not by strength of evidence, and neither are the 33 options inside them. A lot of what works in this space has never had the trial run, and sorting by trial count would bury exactly the compounds you came looking for.

Educational and research reference only — not medical advice, and not a recommendation for human use. Mechanistic predictions are exactly that: what the biology suggests should happen, which is not the same as what has been shown to happen.